Shares of development-stage biotech Sarepta Therapeutics (SRPT -6.52%) popped 4.3% today after the company released data from the extension phase of its phase 2b clinical study for its Duchenne muscular dystrophy drug eteplirsen. Like most stocks in this space, Sarepta faces a number of risks; eteplirsen, for instance, is the company's main asset, and any setbacks to its development, regulatory delays, or safety issues could make shares plunge. Also, Sarepta is running a very small clinical trial and it may not be able to file for accelerated approval. However, to date, the drug has displayed a clean safety profile and continues to show efficacy. In the following video, health-care analyst Max Macaluso discusses these topics and what today's news means for investors.